Article Data

  • Views 514
  • Dowloads 136

Original Research

Open Access

Doxorubicin hydrochloride and bevacizumab for the patients with platinum-taxane resistant ovarian cancer

  • T. Ota1,*,
  • Y. Sugimori2
  • K. Fujino1
  • T. Ujihira1
  • S. Kusunoki2
  • M. Kimura1
  • Y. Terao1
  • D. Ogishima2
  • S. Takeda1

1Department of Obstetrics and Gynecology, Faculty of Medicine, Juntendo University, Tokyo, Japan

2Department of Obstetrics and Gynecology, Juntendo Nerima Hospital, Tokyo, Japan

DOI: 10.12892/ejgo4066.2018 Vol.39,Issue 6,December 2018 pp.889-893

Published: 15 December 2018

*Corresponding Author(s): T. Ota E-mail: tota@juntendo.ac.jp

Abstract

Introduction. The authors conducted a retrospective study examine the efficacy of pegylated liposomal doxorubicin (PLD) with/without bevacizumab in patients with carboplatin/paclitaxel (TC)-resistant/refractory ovarian cancer. Material and Methods: Subjects were 81 patients with TC-resistant/refractory ovarian, peritoneal, or tubal carcinoma who received second-line PLD alone (n=59) or PLD plus bevacizumab combination (n=22) chemotherapy after TC failure. Efficacy and safety of the regimens were compared between the two groups. Results. The average number of cycles of PLD and PLD plus bevacizumab were 5.9 and 5.3, respectively. The response to the chemotherapy (complete response and partial response) was 25.4% in the PLD group and 45.5% in the PLD plus bevacizumab group (p = 0.01). The overall response (complete response, partial response, and stable disease) was 48.3% and 86.4%, respectively (p = 0.002). Median time to disease progression was 7.7 and 9.5 months, respectively (p = 0.344), and median survival time was 16.4 and 13.2 months, respectively (p = 0.556). Grade 3-4 hematologic and non-hematologic toxicities did not differ between the two groups. Next, patients were divided into two groups: those refractory to initial platinum-based chemotherapy (n=46) and those who were platinum-sensitive (n=35). In platinum refractory patients, median time to disease progression in PLD and in PLD plus bevacizumab was 5.4 and 11.9 months, respectively (p = 0.466). Conclusion. In terms of tumor response and survival time, bevacizumab provides a clinical benefit for the patients with platinum-resistant/refractory ovarian cancer. Further, the addition of bevacizumab to PLD may provide longer PFS for patients with disease that is refractory to first-line platinum based chemotherapy.

Keywords

Platinum-resistant/refractory ovarian cancer; Pegylated liposomal doxorubicin; Bevacizumab.

Cite and Share

T. Ota,Y. Sugimori,K. Fujino,T. Ujihira,S. Kusunoki,M. Kimura,Y. Terao,D. Ogishima,S. Takeda. Doxorubicin hydrochloride and bevacizumab for the patients with platinum-taxane resistant ovarian cancer. European Journal of Gynaecological Oncology. 2018. 39(6);889-893.

References

[1] McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al.: “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer”. N. Eng. J. Med., 1996, 334, 1.

[2] Bookman M.A., Greer B.E., Ozols R.F.: “Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5”. Int. J. Gynecol. Cancer, 2003, 13, 735.

[3] Cannistra S.A.: “Cancer of the ovary”. N. Eng. J. Med., 2004, 351, 2519.

[4] Stuart G.C., Kitchener H., Bacon M., duBois A., Friedlander M., Ledermann J., et al.: “participants of 4th Ovarian Cancer Consensus Figure 4. — Kaplan-Meier curves of progression-free survival (PFS) per treatment among patients with refractory disease. Conference (OCCC); Gynecologic Cancer Intergroup. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference”. Int. J. Gynecol. Cancer, 2011, 21, 750.

[5] Buda A., Floriani I., Rossi R., Colombo N., Torri V., Conte P.F., et al.: “Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian collaborative study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group”. Br. J. Cancer, 2004, 90, 2112.

[6] Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J.: ‘Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan”. J. Clin. Oncol., 2001, 19, 3312.

[7] Vergote I., Finkler N., del Campo J., Lohr A., Hunter J., Matei D., et al.: “ASSIST-1 study group: Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line ther- apy in patients with platinum-refractory or -resistant ovarian cancer” Eur. J. Cancer, 2009, 45, 2324.

[8] Mutch D.G., Orlando M., Goss T., Teneriello M.G., Gordon A.N., McMeekin S.D., et al.: “Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer”. J. Clin. Oncol., 2007, 25, 2811.

[9] ten Bokkel Huinink W., Gore M., Carmichael J., Teneriello M.G., Gordon A.N., McMeekin S.D., et al.: “Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer”. J. Clin. Oncol., 1997, 15, 2183.

[10] Cohn D., Valmadre S., Resnick K., Eaton L.A., Copeland L.J., Fowler J.M.: “Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer”. Gynecol. Oncol., 2006, 102, 134.

[11] Numnum T., Rocconi R., Whitworth J., Barnes M.N.: “The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma”. Gynecol. Oncol., 2006, 102, 425.

[12] Burger R.A., Sill M.W., Monk B.J., Barnes M.N.: “Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study”. J. Clin. Oncol., 2007, 25, 5165.

[13] Cannistra S.A., Matulonis U.A., Penson R.T., Hambleton J., Dupont J., Mackey H., et al.: ‘Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer”. J. Clin. Oncol., 2007, 25, 5180.

[14] McGonigle K.F., Muntz H.G., Vuky J., Hambleton J., Dupont J., Mackey H., et al.: “Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study”. Cancer, 2011, 117, 3731.

[15] Garcia A.A., Hirte H., Fleming G., Yang D., Tsao-Wei D.D., Roman L., et al.: “Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia”. J. Clin. Oncol., 2008, 26, 76.

[16] Presta L.G., Chen H., O’Connor S.J., Chisholm V., Meng YG, Krummen L, Winkler M, et al.: “Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders”. Cancer Res., 1997, 57, 4593.

[17] Ignoffo R.J.: “Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor”. Am. J. Health Syst. Pharm., 2004, 61, S21.

[18] Friedlander M., Butow P., Stockler M., Gainford C., Martyn J., Oza A., et al.: “Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer”. Int. J. Gynecol. Cancer, 2009, 19, S44.

[19] Ota T., Takeshima N., Takizawa K.: “Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?” Eur. J. Gynaecol. Oncol., 2011, 32, 471.

[20] Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., et al.: “Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA openlabel randomized phase III trial”. J. Clin. Oncol., 2014, 32, 1302.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top